PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections
GlobeNewsWire6/1/2026Neutral
PYPD
PolyPidNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$102.20M
P/E Ratio
—
EPS
$-1.67
Beta
1.40
52W High
$5.62
52W Low
$3.06
50-Day MA
$4.71
200-Day MA
$4.23
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About PolyPid
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-31.73M |
| Operating Margin | 0.00% |
| Return on Equity | -759.00% |
| Return on Assets | -115.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.46 |
| Price-to-Book | 10.96 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $19.17M |
| Float | $10.91M |
| % Insiders | 21.23% |
| % Institutions | 34.85% |
Historical Volatility
HV 10-Day
77.76%
HV 20-Day
63.84%
HV 30-Day
63.89%
HV 60-Day
55.56%
HV Rank
96.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.25 target)
1
Strong Buy3
BuyLatest News
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.
GlobeNewsWire5/20/2026Neutral
PolyPid Q1 Earnings Call Highlights
PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.
MarketBeat5/13/2026Neutral
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
Seeking Alpha5/13/2026Neutral
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its first quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026.
GlobeNewsWire5/6/2026Neutral
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California.
GlobeNewsWire4/28/2026Neutral
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site
GlobeNewsWire4/13/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026